Mo­men­ta’s failed pan­cre­at­ic can­cer drug is giv­en a mid­night fu­ner­al

Pan­cre­at­ic can­cer has claimed an­oth­er biotech vic­tim. The tough on­col­o­gy tar­get proved re­sis­tant to Mo­men­ta Phar­ma­ceu­ti­cals’ necu­paranib at the halfway point in their Phase II …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.